Q32 Bio Inc. (NASDAQ:QTTB) Receives $29.86 Average PT from Analysts

Shares of Q32 Bio Inc. (NASDAQ:QTTB) have been given a consensus rating of “Hold” by the eight analysts that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $24.86.

QTTB has been the subject of several recent analyst reports. Leerink Partnrs downgraded shares of Q32 Bio from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Leerink Partners restated a “market perform” rating and issued a $9.00 price objective (down previously from $68.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. Raymond James reaffirmed an “outperform” rating and set a $22.00 price objective (down previously from $90.00) on shares of Q32 Bio in a research note on Wednesday, December 11th. Wells Fargo & Company reissued an “equal weight” rating and issued a $16.00 target price (down from $95.00) on shares of Q32 Bio in a research note on Wednesday, December 11th. Finally, Piper Sandler lowered Q32 Bio from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $20.00 to $4.00 in a research report on Tuesday.

Hedge Funds Weigh In On Q32 Bio

Large investors have recently added to or reduced their stakes in the company. Values First Advisors Inc. acquired a new position in shares of Q32 Bio during the third quarter worth about $33,000. Hussman Strategic Advisors Inc. bought a new stake in Q32 Bio in the 4th quarter valued at approximately $36,000. AXQ Capital LP bought a new stake in Q32 Bio in the 4th quarter valued at approximately $36,000. Raymond James Financial Inc. acquired a new position in Q32 Bio during the 4th quarter worth approximately $37,000. Finally, Drive Wealth Management LLC bought a new position in shares of Q32 Bio during the 4th quarter worth approximately $38,000. Institutional investors own 31.32% of the company’s stock.

Q32 Bio Stock Performance

Shares of QTTB stock opened at $2.66 on Friday. The stock has a market cap of $32.40 million, a PE ratio of -0.19 and a beta of -0.32. The stock has a 50-day moving average of $5.48 and a 200-day moving average of $28.53. The company has a debt-to-equity ratio of 0.61, a current ratio of 6.53 and a quick ratio of 6.53. Q32 Bio has a one year low of $2.59 and a one year high of $53.79.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.